AK112 (Yiwoxidan Anti)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AK112 (Yiwoxidan Anti), covering 2026-03-23 to 2026-03-23. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study [Phase 2]